Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Medtronic to acquire Medicrea for EUR 7.00 per share » 05:30
07/15/20
07/15
05:30
07/15/20
05:30
MDT

Medtronic

$94.65 /

+1.92 (+2.07%)

Medtronic and Medicrea…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MDT Medtronic
$94.65 /

+1.92 (+2.07%)

MDT Medtronic
$94.65 /

+1.92 (+2.07%)

07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
MDT Medtronic
$94.65 /

+1.92 (+2.07%)

MDT Medtronic
$94.65 /

+1.92 (+2.07%)

MDT Medtronic
$94.65 /

+1.92 (+2.07%)

MDT Medtronic
$94.65 /

+1.92 (+2.07%)

Tuesday
Periodicals
Boston Scientific exploring sale of snake venom unit, Bloomberg reports » 11:29
07/14/20
07/14
11:29
07/14/20
11:29
BSX

Boston Scientific

$34.60 /

+0.175 (+0.51%)

Boston Scientific is…

Boston Scientific is working with advisers to explore the sale of its specialty pharmaceutical business focused on treatments for snake venom, Bloomberg reports, citing people with knowledge of the matter. The business could be worth could be worth close to $1B, Bloomberg adds.

ShowHide Related Items >><<
BSX Boston Scientific
$34.60 /

+0.175 (+0.51%)

BSX Boston Scientific
$34.60 /

+0.175 (+0.51%)

05/10/20 Piper Sandler
FLX to further strengthen Boston category leadership in LAAC, says Piper Sandler
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform at SVB Leerink on slower recovery
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform from Outperform at SVB Leerink
BSX Boston Scientific
$34.60 /

+0.175 (+0.51%)

  • 22
    May
BSX Boston Scientific
$34.60 /

+0.175 (+0.51%)

BSX Boston Scientific
$34.60 /

+0.175 (+0.51%)

Hot Stocks
Titan Medical sends update letter to shareholders » 08:04
07/14/20
07/14
08:04
07/14/20
08:04
TMDI

Titan Medical

$0.81 /

+0.0079 (+0.99%)

, MDT

Medtronic

$92.73 /

+1.9 (+2.09%)

Titan Medical (TMDI)…

Titan Medical (TMDI) issued an update letter to its shareholders. The letter was authored by David McNally, president and CEO, chairman. The letter said, "As we commence the second half of 2020, I provide you with a brief review of the first half and outline our focus for the remainder of the year... On June 3, 2020, we entered into several agreements with an affiliate of Medtronic plc (MDT), including a development and license agreement to further the development of robotic assisted surgical technologies, as well as a separate license agreement in respect of certain intellectual property of Titan. The development and license agreement provides for the development of robotic assisted surgical technologies for use by both Titan and Medtronic in their respective robotic assisted surgery businesses. As technology milestones are completed and verified, we will be entitled to receive a series of license payments totaling up to $31 million for Medtronic's rights to such technologies. Our engineering team and product development partners are working toward the achievement of the first milestone in October 2020. If successful, Titan will receive a payment of $10 million before proceeding to the second of the three development milestones, to be completed in 2021. Under the terms of the separate license agreement, Medtronic has licensed certain robotic assisted surgical technologies from Titan for an upfront license payment of $10 million, which we received in June 2020. Titan retains the rights to continue to develop and commercialize those technologies for its own business. These agreements with Medtronic allow Titan to continue to develop its single-port robotic surgical technologies while sharing our expertise and technologies with Medtronic. Through the $10 million license payment and $1.5 million loan from Medtronic, and the over $20 million raised in public equity, we have been able to resume product development of our single-port robotic surgical system. Robotic systems designed for surgery are highly technical and complex pieces of equipment, involving medical-grade software and numerous electro-mechanical systems, precise surgical instruments and sterile interface components, all designed for instinctive use and successful surgical outcomes. To facilitate the unique design and development of our system, Titan has engaged individuals and third parties with specialized competencies for assistance with certain aspects of our system such as our innovative dual-view camera system, multi-articulating instruments and simulation training software. We have also established a U.S. subsidiary to initially focus on product development activities, which is based at our new dedicated, purpose-built space in North Carolina's Research Triangle, a leading high-tech and medical technology hub, which is also in close proximity to our development partners. The recruitment of highly skilled and experienced technical personnel to manage, execute and provide in-house expertise in product development is well underway. The opportunity for single-port robotic surgery appears promising, with initial and on-going clinical success being reported by surgeons using Intuitive Surgical's da Vinci SP(R), the only commercially available single-port offering, but currently with surgical indications outside our initial target area. We believe that our robotic assisted surgical system, having been designed with a focus on single-port surgery, may provide competitive advantages for physicians and their clinical teams, hospitals and patients. Should we be able to complete product development and achieve regulatory clearance in a timely manner, upon commercialization we expect our single-port system to expand the market for robotic assisted surgery with attractive pricing, a reduced operating room footprint and greater portability within the hospital. With these target product attributes, we intend to focus early commercialization efforts on U.S. ambulatory surgery centers wishing to perform benign procedures in a lower-cost setting compared to hospitals."

ShowHide Related Items >><<
TMDI Titan Medical
$0.81 /

+0.0079 (+0.99%)

MDT Medtronic
$92.73 /

+1.9 (+2.09%)

TMDI Titan Medical
$0.81 /

+0.0079 (+0.99%)

03/31/20 Piper Sandler
Titan Medical price target lowered to $1 from $1.50 at Piper Sandler
12/23/19 Piper Sandler
Titan Medical price target cut to $1.50 from $2.50 at Piper Jaffray
11/18/19 Piper Sandler
Titan Medical transferred with an Overweight rating at Piper Jaffray
10/16/19 Maxim
Titan Medical downgraded to Hold from Buy at Maxim
MDT Medtronic
$92.73 /

+1.9 (+2.09%)

07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
MDT Medtronic
$92.73 /

+1.9 (+2.09%)

  • 24
    Sep
MDT Medtronic
$92.73 /

+1.9 (+2.09%)

MDT Medtronic
$92.73 /

+1.9 (+2.09%)

MDT Medtronic
$92.73 /

+1.9 (+2.09%)

Over a week ago
Recommendations
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler » 11:02
07/09/20
07/09
11:02
07/09/20
11:02
TNDM

TNDM

/

+

, MDT

Medtronic

$90.48 /

-1.16 (-1.27%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien says Tandem Diabetes' (TNDM) non-exclusive patent cross-license agreement with Medtronic (MDT) for certain technologies relating to diabetes is meant to mitigate any potential legal disagreements. The agreement has certain exclusions and includes a provision not to clone each other's products.

ShowHide Related Items >><<
TNDM TNDM
/

+

MDT Medtronic
$90.48 /

-1.16 (-1.27%)

TNDM TNDM
/

+

07/07/20 Cowen
Tandem Diabetes price target raised to $110 from $85 at Cowen
07/06/20
Fly Intel: Top five analyst upgrades
07/06/20 Citi
Tandem Diabetes upgraded to Buy from Neutral at Citi
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
MDT Medtronic
$90.48 /

-1.16 (-1.27%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
TNDM TNDM
/

+

MDT Medtronic
$90.48 /

-1.16 (-1.27%)

MDT Medtronic
$90.48 /

-1.16 (-1.27%)

TNDM TNDM
/

+

MDT Medtronic
$90.48 /

-1.16 (-1.27%)

MDT Medtronic
$90.48 /

-1.16 (-1.27%)

Hot Stocks
Medtronic, Tandem enter non-exclusive patent cross-license agreement » 11:01
07/09/20
07/09
11:01
07/09/20
11:01
MDT

Medtronic

$90.40 /

-1.24 (-1.35%)

, TNDM

TNDM

/

+

Medtronic (MDT) and…

Medtronic (MDT) and Tandem Diabetes Care (TNDM) announced earlier that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. "Cross-licensing each other's patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements," they said in a statement. The companies added, "With certain exclusions, this agreement applies to the companies' existing products, as well as new products for at least the next five years, and also includes a provision not to clone one another's products. No payments will be exchanged as part of this agreement and further terms were not disclosed."

ShowHide Related Items >><<
TNDM TNDM
/

+

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
TNDM TNDM
/

+

07/07/20 Cowen
Tandem Diabetes price target raised to $110 from $85 at Cowen
07/06/20
Fly Intel: Top five analyst upgrades
07/06/20 Citi
Tandem Diabetes upgraded to Buy from Neutral at Citi
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
TNDM TNDM
/

+

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

TNDM TNDM
/

+

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

MDT Medtronic
$90.40 /

-1.24 (-1.35%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:18
07/08/20
07/08
16:18
07/08/20
16:18
LEVI

Levi Strauss

$12.68 /

-1.195 (-8.62%)

, FB

Facebook

$243.58 /

+2.51 (+1.04%)

, BIIB

Biogen

$280.15 /

+11.97 (+4.46%)

, ALL

Allstate

$88.20 /

-4.38 (-4.73%)

, NGHC

National General

$33.73 /

+13.29 (+65.02%)

, TWTR

Twitter

$35.39 /

+2.41 (+7.31%)

, MRNA

Moderna

$61.58 /

+0.5 (+0.82%)

, GM

General Motors

$24.93 /

-0.19 (-0.76%)

, FCAU

Fiat Chrysler

$9.99 /

-0.09 (-0.89%)

, XENT

Intersect ENT

$17.98 /

+4.07 (+29.26%)

, MDT

Medtronic

$91.64 /

-0.05 (-0.05%)

, NKLA

Nikola

$54.03 /

+13.78 (+34.24%)

, GILT

Gilat Satellite

$5.20 /

-0.905 (-14.82%)

, CMTL

Comtech

$15.87 /

+0.32 (+2.06%)

Stocks continue to rise…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

06/16/20 Exane BNP Paribas
Levi Strauss initiated with an Outperform at Exane BNP Paribas
04/09/20 Guggenheim
Levi Strauss price target lowered to $16 from $26 at Guggenheim
04/08/20 Citi
Levi Strauss has ample liquidity and remains 'strong brand,' says Citi
03/18/20 BofA
Levi Strauss downgraded to Neutral with $15 price target at BofA
FB Facebook
$243.58 /

+2.51 (+1.04%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
BIIB Biogen
$280.15 /

+11.97 (+4.46%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$88.20 /

-4.38 (-4.73%)

07/09/20 B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
07/09/20 Citi
Allstate acquisition of National an incremental positive, says Citi
07/09/20 JMP Securities
National General downgraded to Market Perform from Outperform at JMP Securities
07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
NGHC National General
$33.73 /

+13.29 (+65.02%)

07/09/20 B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
TWTR Twitter
$35.39 /

+2.41 (+7.31%)

07/09/20 Citi
Twitter shares overreacted to paid service potential, says Citi
07/08/20 Rosenblatt
Rosenblatt says 'highly unlikely' Twitter considering paid subscription tiers
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
MRNA Moderna
$61.58 /

+0.5 (+0.82%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
GM General Motors
$24.93 /

-0.19 (-0.76%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

07/08/20 Oppenheimer
Takeout bid of $17 for Intersect ENT would be 'reasonable,' says Oppenheimer
06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
MDT Medtronic
$91.64 /

-0.05 (-0.05%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$54.03 /

+13.78 (+34.24%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

  • 19
    May
  • 12
    Feb
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:01
07/08/20
07/08
12:01
07/08/20
12:01
FB

Facebook

$238.53 /

-2.54 (-1.05%)

, BIIB

Biogen

$282.02 /

+13.84 (+5.16%)

, ALL

Allstate

$89.20 /

-3.38 (-3.65%)

, NGHC

National General

$33.60 /

+13.155 (+64.36%)

, XENT

Intersect ENT

$17.96 /

+4.05 (+29.12%)

, MDT

Medtronic

$90.66 /

-1.03 (-1.12%)

, NKLA

Nikola

$49.02 /

+8.77 (+21.79%)

, GILT

Gilat Satellite

$5.21 /

-0.895 (-14.66%)

, CMTL

Comtech

$15.69 /

+0.14 (+0.90%)

Stocks are marginally…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.96 /

+4.05 (+29.12%)

NKLA Nikola
$49.02 /

+8.77 (+21.79%)

NGHC National General
$33.60 /

+13.155 (+64.36%)

MDT Medtronic
$90.66 /

-1.03 (-1.12%)

GILT Gilat Satellite
$5.21 /

-0.895 (-14.66%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

CMTL Comtech
$15.69 /

+0.14 (+0.90%)

BIIB Biogen
$282.02 /

+13.84 (+5.16%)

ALL Allstate
$89.20 /

-3.38 (-3.65%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
BIIB Biogen
$282.02 /

+13.84 (+5.16%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$89.20 /

-3.38 (-3.65%)

07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
07/08/20 B. Riley FBR
National General price target raised to $34.50 from $28 at B. Riley FBR
06/25/20
Fly Intel: Top five analyst upgrades
06/25/20 Credit Suisse
Allstate upgraded to Neutral from Underperform at Credit Suisse
NGHC National General
$33.60 /

+13.155 (+64.36%)

04/08/20
Fly Intel: Top five analyst initiations
04/08/20 JPMorgan
National General initiated with a Neutral at JPMorgan
XENT Intersect ENT
$17.96 /

+4.05 (+29.12%)

06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
05/12/20 Canaccord
Intersect ENT downgraded to Hold from Buy at Canaccord
MDT Medtronic
$90.66 /

-1.03 (-1.12%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$49.02 /

+8.77 (+21.79%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.21 /

-0.895 (-14.66%)

CMTL Comtech
$15.69 /

+0.14 (+0.90%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.96 /

+4.05 (+29.12%)

NGHC National General
$33.60 /

+13.155 (+64.36%)

MDT Medtronic
$90.66 /

-1.03 (-1.12%)

GILT Gilat Satellite
$5.21 /

-0.895 (-14.66%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

CMTL Comtech
$15.69 /

+0.14 (+0.90%)

BIIB Biogen
$282.02 /

+13.84 (+5.16%)

ALL Allstate
$89.20 /

-3.38 (-3.65%)

XENT Intersect ENT
$17.96 /

+4.05 (+29.12%)

NKLA Nikola
$49.02 /

+8.77 (+21.79%)

MDT Medtronic
$90.66 /

-1.03 (-1.12%)

GILT Gilat Satellite
$5.21 /

-0.895 (-14.66%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

BIIB Biogen
$282.02 /

+13.84 (+5.16%)

XENT Intersect ENT
$17.96 /

+4.05 (+29.12%)

NKLA Nikola
$49.02 /

+8.77 (+21.79%)

MDT Medtronic
$90.66 /

-1.03 (-1.12%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

CMTL Comtech
$15.69 /

+0.14 (+0.90%)

BIIB Biogen
$282.02 /

+13.84 (+5.16%)

ALL Allstate
$89.20 /

-3.38 (-3.65%)

NKLA Nikola
$49.02 /

+8.77 (+21.79%)

MDT Medtronic
$90.66 /

-1.03 (-1.12%)

FB Facebook
$238.53 /

-2.54 (-1.05%)

BIIB Biogen
$282.02 /

+13.84 (+5.16%)

Options
Boston Scientific put volume heavy and directionally bearish » 11:35
07/08/20
07/08
11:35
07/08/20
11:35
BSX

Boston Scientific

$34.25 /

-0.39 (-1.13%)

Bearish flow noted in…

Bearish flow noted in Boston Scientific with 3,834 puts trading, or 2x expected. Most active are Jul-20 34 puts and Nov-20 29 puts, with total volume in those strikes near 1,700 contracts. The Put/Call Ratio is 4.85, while ATM IV is up over 1 point on the day. Earnings are expected on July 29th.

ShowHide Related Items >><<
BSX Boston Scientific
$34.25 /

-0.39 (-1.13%)

BSX Boston Scientific
$34.25 /

-0.39 (-1.13%)

05/10/20 Piper Sandler
FLX to further strengthen Boston category leadership in LAAC, says Piper Sandler
04/28/20 Piper Sandler
Untreated heart attacks negative for Abiomed, says Piper Sandler
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform at SVB Leerink on slower recovery
04/22/20 SVB Leerink
Boston Scientific downgraded to Market Perform from Outperform at SVB Leerink
BSX Boston Scientific
$34.25 /

-0.39 (-1.13%)

  • 22
    May
BSX Boston Scientific
$34.25 /

-0.39 (-1.13%)

BSX Boston Scientific
$34.25 /

-0.39 (-1.13%)

Periodicals
Intersect ENT reviewing Medtronic takeover offer, Bloomberg says » 20:59
07/07/20
07/07
20:59
07/07/20
20:59
XENT

Intersect ENT

$13.91 /

-0.25 (-1.77%)

, MDT

Medtronic

$91.69 /

-1.51 (-1.62%)

Intersect's (XENT)…

Intersect's (XENT) board of directors is reviewing the offer made by Medtronic (MDT), Bloomberg's Nabila Ahmed and Ed Hammond report, citing people familiar with the matter. The report adds that the discussions are in the early stages and Medtronic's plans could still change. Reference Link

ShowHide Related Items >><<
XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
05/12/20 Canaccord
Intersect ENT downgraded to Hold from Buy at Canaccord
MDT Medtronic
$91.69 /

-1.51 (-1.62%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

Periodicals
Medtronic makes bid to acquire Intersect ENT, Bloomberg says  19:24
07/07/20
07/07
19:24
07/07/20
19:24
XENT

Intersect ENT

$13.91 /

-0.25 (-1.77%)

, MDT

Medtronic

$91.69 /

-1.51 (-1.62%)

 
ShowHide Related Items >><<
XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
05/12/20 Canaccord
Intersect ENT downgraded to Hold from Buy at Canaccord
MDT Medtronic
$91.69 /

-1.51 (-1.62%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

XENT Intersect ENT
$13.91 /

-0.25 (-1.77%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

MDT Medtronic
$91.69 /

-1.51 (-1.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.